5-Hydroxytryptophan / Vitamin B6 ( DrugBank: Vitamin B6 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05030129 (ClinicalTrials.gov) | September 15, 2021 | 5/8/2021 | Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome | An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome | Fragile X Syndrome | Dietary Supplement: 5-Hydroxytryptophan / Vitamin B6;Drug: Ergoloid Mesylate;Other: Placebo | Elizabeth Berry-Kravis | NULL | Not yet recruiting | 18 Years | 45 Years | Male | 15 | Phase 2 | NULL |